Mobic tablets (meloxicam) 10 mg from Japan (arthritis, osteoarthritis)

General information about Japanese Mobic tablets (meloxicam) 10 mg

Package details: 100 tablets

Manufacturer: Japan Boehringer Ingelheim, Japan.

Active ingredient: Meloxicam 10 mg

Medical effect: Mobic tablets (meloxicam) 10 mg from Japan suppresses activity of prostaglandin and relieves pain caused by inflammation. Mobic tablets (meloxicam) are effective for treatment of:

• rheumatoid arthritis,
• osteoarthritis,
• lumbar pain,
• frozen shoulder,
• neck-shoulder-arm syndrome.

Contraindications and precautions: do not use in patients with peptic ulcer, dysemia, high cholesterol, liver, kidney or heart disease, hypertension, diabetes or aspirin asthma. Do not use in pregnant or breastfeeding women. When used with other drugs, be sure to consult with your doctor to avoid the interaction between the medicines. Do not drive a car or operate dangerous machinery because meloxicam can cause dizziness or failing focus adjustment.

Dosage and Administration of Mobic tablets (meloxicam) 10 mg from Japan: take 1 tablet 1 time a day after meal. A consulting doctor can adjust the dosage, but the maximum of 1.5 tablets should never be exceeded. In general, use this strong painkiller as short a period as possible.

Regarding the effectiveness of Mobic tablets (meloxicam) 10 mg from Japan.

Mobic tablets (meloxicam) 10 mg from Japan help to treat inflammation and pain in rheumatic diseases and osteoarthritis. This nonsteroidal anti-inflammatory drug was developed in 1977 by Boehringer Ingelheim. Mobic tablets 10 mg have fewer gastrointestinal side effects than naproxen, diclofenac or piroxicam. Meloxicam also has fewer thromboembolic complications than diclofenac (G. Singh, S. Lanes, G. Triadafilopoulos. “Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients”. The American Journal of Medicine. 2004, 117 (9): 100–6). And moreover, probably all other nonsteroidal anti-inflammatory drugs are not cyclooxygenase-2-selective. At the same time Mobic tablets block cyclooxygenase-2 rather than cyclooxygenase-1 (C. Hawkey, A. Kahan et al. “Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients”. Rheumatology, 1998. 37 (9): 937–945(9)).